Wockhardt Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Wockhardt Ltd. on BSE

Load latest

Wockhardt Ltd.

07 Feb 2025

1296.70

-4.91%

Board Meeting

WOCKHARDT LTD. - 532300 - Board Meeting Outcome for Outcome Of The Board Meeting

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'); and in continuation to our letter bearing reference no. Ref. No.: WOCK/SEC/SE/2024-25/086 dated 3rd February, 2025, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 7th February, 2025, inter-alia, have approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 31st December, 2024

pdf

Wockhardt Ltd.

03 Feb 2025

1296.70

-4.91%

Board Meeting

WOCKHARDT LTD. - 532300 - Board Meeting Intimation for Intimation Of The Meeting Of Board Of …

BSE India

WOCKHARDT LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2025 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI (Listing Obligations and is closure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company will be held on Friday, 7th February, 2025, inter-alia, to consider and approve the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended 31st December, 2024

pdf

Wockhardt Ltd.

31 Jan 2025, 08:58AM

1296.70

-4.91%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of SEBI Listing Regulations, please find enclosed Press Release - "Wockhardt''s Zaynich (Zidebactam/Cefepime, WCK 5222) achieves highest-ever efficacy meeting superiority in a global, pivotal, registration-enabling Phase III study in complicated urinary infection (cUTI) achieving 96.8% clinical cure rate"

pdf

Wockhardt Ltd.

14 Jan 2025

1296.70

-4.91%

Company Update

WOCKHARDT LTD. - 532300 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find attached the Compliance Certificate received from MUFG Intime India Pvt Ltd (Formerly known as Link Intime India Pvt Ltd), RTA of the Company for the Quarter ended 31st December, 2024.

pdf

Wockhardt Ltd.

13 Jan 2025

1296.70

-4.91%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of SEBI Listing Regulations, please find attached Press Release titled "Zaynich(Zidebactum/Cefepime. WCK 5222)achieves over 97% Efficacy in Clinical Study for serious infections caused by by Meropenem-Resistant Gram-Negative Pathogens."

pdf

Wockhardt Ltd.

02 Jan 2025

1296.70

-4.91%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of the Listing Regulations, please find attached Press Release titled- Indian Drug Regulator Approves Wockhardt''s New Generation Oral Antibiotic MiqnafR (Nafithromycin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP).

pdf

Wockhardt Ltd.

26 Dec 2024

1296.70

-4.91%

SAST

WOCKHARDT LTD. - 532300 - Closure of Trading Window

BSE India

This is to inform you that pursuant to Company''s Code of Conduct for regulating, monitoring and reporting trading by Designated persons, the trading window for dealing in the equity shares of the Company will be closed from 1st January, 2025 until 48 hours after the declaration of unaudited financial results for quarter and nine months ended on 31st December, 2024.

pdf

Wockhardt Ltd.

16 Dec 2024

1296.70

-4.91%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of SEBI Listing Regulations, please find attached Press Release titled, "Zaynich TM (Zidebactam/Cefepime, WCK 5222) enables US cancer patient undergo successful liver transplant and resume chemotheraphy by eradicating dual extreme-drug resistant Gram negative pathogens"

pdf

Wockhardt Ltd.

27 Nov 2024

1296.70

-4.91%

Corp. Note

WOCKHARDT LTD. - 532300 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate …

BSE India

Pursuant to the requirement of the Regulation 39(3) of the SEBI Listing Regulations, we wish to inform you that our RTA has intimated about receipt of the request for the issuance of Duplicate Share Certificate in lieu of the Original Certificate lost/misplaced.

pdf

Wockhardt Ltd.

21 Nov 2024

1296.70

-4.91%

Corp. Note

WOCKHARDT LTD. - 532300 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate …

BSE India

Pursuant to the requirement of the Regulation 39(3) of the SEBI Listing Regulations, we wish to inform the Stock Exchange that our RTA has intimated about receipt of the Duplicate Share Certificates in lieu of the original Share Certificate reported lost/misplaced.

pdf

Is Wockhardt Ltd. worth buying?

443 Votes:

Buy 73.14%

Sell 17.38%

Hold 9.48%